Related Experiment Video
Updated: Apr 25, 2026
Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
Published on: September 8, 2023
Clinical challenges in targeting anaplastic lymphoma kinase in advanced non-small cell lung cancer
Namrata Vijayvergia1, Ranee Mehra
1Fox Chase Cancer Center, 393 Cottman Avenue, Philadelphia, PA, 19111, USA.
Abstract:
The revolution in individualized therapy for patients with advanced non-small cell lung cancer (NSCLC) has seen the emergence of a number of molecularly targeted therapies for distinct patient molecular subgroups. Activating anaplastic lymphoma kinase (ALK)-gene rearrangement has been detected in 3-7 % of NSCLC cases, and the ALK inhibitor crizotinib is now an approved treatment for patients with tumors harboring this event. However, resistance to ALK-targeted therapies is a ubiquitous problem in the management of advanced ALK-positive NSCLC and can be mediated by secondary kinase mutations or the activation of compensatory alternative oncogenic drivers. New, more potent ALK inhibitors such as ceritinib (LDK378), alectinib (CH5424802), and AP26113 are now emerging, together with an increased knowledge of the molecular basis of resistance. There is a need to evaluate the optimal clinical application of these new agents, either as sequential therapies or in combination with other targeted agents, to combat resistance and prolong survival in patients with ALK-positive NSCLC. The remarkable clinical activity of ALK inhibitors also emphasizes the importance of optimal diagnostic testing algorithms, to ensure that all eligible patients receive these breakthrough therapies.
Insights
New anaplastic lymphoma kinase (ALK) inhibitors offer hope for advanced non-small cell lung cancer (NSCLC) patients, addressing resistance to current therapies. Optimal diagnostic testing is crucial to ensure all eligible patients benefit from these targeted treatments.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- Individualized therapy has revolutionized advanced non-small cell lung cancer (NSCLC) treatment.
- Anaplastic lymphoma kinase (ALK)-gene rearrangement occurs in 3-7% of NSCLC cases, with crizotinib as an approved ALK inhibitor.
- Resistance to ALK inhibitors is common, driven by secondary mutations or alternative oncogenic drivers.
Purpose of the Study:
- To review the emergence of new ALK inhibitors and the molecular basis of resistance.
- To discuss the optimal clinical application of novel ALK inhibitors in combating resistance and prolonging survival.
- To highlight the importance of diagnostic testing for ALK-positive NSCLC patients.
Main Methods:
- Literature review of ALK inhibitors and resistance mechanisms in NSCLC.
- Analysis of emerging ALK inhibitors (ceritinib, alectinib, AP26113).
- Discussion of clinical strategies for managing ALK-positive NSCLC.
Main Results:
- New potent ALK inhibitors are available, offering improved efficacy.
- Understanding of resistance mechanisms is increasing.
- Optimal diagnostic testing is essential for patient selection.
Conclusions:
- Novel ALK inhibitors show promise for overcoming resistance in ALK-positive NSCLC.
- Sequential or combination therapies with new agents require evaluation.
- Accurate diagnostic testing ensures access to life-saving targeted therapies.
More Related Videos
06:51Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer
Published on: July 21, 2018
06:08Establishment and Characterization of Patient-Derived Xenograft Models of Anaplastic Thyroid Carcinoma and Head and Neck Squamous Cell Carcinoma
Published on: June 2, 2023
